Lilly looks to autoimmune drugs

Two local researchers show why Eli Lilly and Co. and its peers are interested in developing medicines to treat autoimmune
diseases: The costs of treating them are growing twice as fast as the prescription drug market.

Dr. Vivianne Beyer
of St. Vincent Health and Dr. Stephen E. Wolverton of the Indiana University School of Medicine examined the trends for treating
psoriasis in the January issue of the Archives of Dermatology, according to a story by BusinessWeek.

Psoriasis, a chronic autoimmune skin disease that affects 4.5 million to 7.5 million people,
costs Americans more than $3 billion each year in medicines, doctors visits, lab tests and monitoring.

The average annual costs for brand-name psoriasis treatments rose by 66 percent from 2000 to
2008, Beyer and Wolverton found. Costs for all prescription drugs rose 31 percent over the same time
period.

One driver of the increase has been new biotech drugs, which range in cost
from $18,000 to $28,000 each year.

Autoimmune disease is one of three key focuses at Lilly’s biotech development
hub in San Diego. Also, in December, Lilly paid $90 million to acquire the rights to an oral treatment for autoimmune diseases
developed by Delaware-based Incyte Corp.

Other autoimmune diseases include rheumatoid arthritis,
lupus and inflammatory bowel syndrome.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}